These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25147236)

  • 1. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
    Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
    Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
    Zuckerman RA; Lucchetti A; Whittington WL; Sánchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
    AIDS; 2009 Feb; 23(4):479-83. PubMed ID: 19169140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
    Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
    Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
    N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
    Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
    Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
    PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
    Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
    AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
    Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
    J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.
    Tan DH; Raboud JM; Kaul R; Grinsztejn B; Cahn P; Walmsley SL
    Trials; 2010 Nov; 11():113. PubMed ID: 21106086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
    Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
    J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.
    Delany S; Mlaba N; Clayton T; Akpomiemie G; Capovilla A; Legoff J; Belec L; Stevens W; Rees H; Mayaud P
    AIDS; 2009 Feb; 23(4):461-9. PubMed ID: 19155993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
    Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
    JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
    Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
    Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
    Roxby AC; Liu AY; Drake AL; Kiarie JN; Richardson B; Lohman-Payne BL; John-Stewart GC; Wald A; De Rosa S; Farquhar C
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):94-8. PubMed ID: 22852760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
    Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
    Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes.
    Martens MG; Fife KH; Leone PA; Dix LP; Brennan CA
    Infect Dis Obstet Gynecol; 2009; 2009():105376. PubMed ID: 19680456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.